Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elsulfavirine + clarithromycin
- Development stage
- Unknown
- Lead developer
- Viriom
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Elsulfavirine + clarithromycin is a drug combination primarily utilized in clinical pharmacology research to investigate drug-drug interactions (DDI). Elsulfavirine, developed by Viriom, is a prodrug of VM-1500A, a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) approved in Russia for the treatment of HIV-1 infection. Clarithromycin is a macrolide antibiotic that, in addition to its antibacterial properties, serves as a potent inhibitor of the Cytochrome P450 3A4 (CYP3A4) enzyme. Because elsulfavirine is extensively metabolized by CYP3A4, co-administration with clarithromycin is studied to evaluate the impact of enzyme inhibition on the systemic exposure, safety, and pharmacokinetics of elsulfavirine and its active metabolite.
- Brand names
- ElpidaBiaxinKlacidFromilid
- Other names
- elsulfavirineclarithromycinVM-1500AVM1500AVM 1500A
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseBacterial 50S ribosomal subunitCA2 (Carbonic Anhydrase 2)CA1 (Carbonic anhydrase 1)
Beyond the preview
Go deeper on elsulfavirine + clarithromycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elsulfavirine + clarithromycin.